Metanephric adenoma is a rare renal epithelial tumor with a low incidence and lack of specific clinical manifestations，resulting in a lack of uniformity in clinical understanding and treatment. Its etiology and pathogenesis are still unclear，and it may be related to the abnormal number and structure of chromosomes 2，7，and 17，as well as mutations in genes such as BRAF V600E，NF1，and NOTCH1，etc. There may be a transformed relationship between this tumor and Wilms’ tumor and papillary renal cell carcinoma. For diagnosis，it has diverse but non-specific clinical manifestations，and it is difficult to accurately differentiate it from other tumors in the imaging examination，and the confirmation of diagnosis relies on pathological and immunohistochemical staining. Treatment is mainly based on surgery to preserve the renal unit，such as partial nephrectomy，etc.，but the difficulty of preoperative diagnosis often leads to over-treatment，and there is a lack of standardized treatment protocols for metastatic posterior renal adenoma. The aim of this article is to provide a reference for the in-depth understanding of posterior renal adenomas and to optimize the clinical diagnosis and treatment strategies.

Metanephric adenoma is a rare renal epithelial tumor with a low incidence and lack of specific clinical manifestations，resulting in a lack of uniformity in clinical understanding and treatment. Its etiology and pathogenesis are still unclear，and it may be related to the abnormal number and structure of chromosomes 2，7，and 17，as well as mutations in genes such as BRAF V600E，NF1，and NOTCH1，etc. There may be a transformed relationship between this tumor and Wilms’ tumor and papillary renal cell carcinoma. For diagnosis，it has diverse but non-specific clinical manifestations，and it is difficult to accurately differentiate it from other tumors in the imaging examination，and the confirmation of diagnosis relies on pathological and immunohistochemical staining. Treatment is mainly based on surgery to preserve the renal unit，such as partial nephrectomy，etc.，but the difficulty of preoperative diagnosis often leads to over-treatment，and there is a lack of standardized treatment protocols for metastatic posterior renal adenoma. The aim of this article is to provide a reference for the in-depth understanding of posterior renal adenomas and to optimize the clinical diagnosis and treatment strategies.

Objective To develop a CD30-targeted CAR-T cell drug based on the multi-chain chimeric antigen re-ceptor T cells(CAR-T)of the bridging protein DAP12,and to study the in vitro and in vivo preclinical efficacy of CD30 CAR-T on Hodgkin lymphoma tumor cells.Methods Through gene synthesis and molecular cloning tech-niques,a CAR plasmid targeting CD30 was designed and constructed,and the obtained lentivirus was packaged.The T cells were transfected with the lentivirus,where the multi-chain CAR-T targeting CD30 was the CD30-KIRS2/Dap12-BB group,the single-chain second-generation CAR-T was the CD30-41BBζ group,and the T cells without virus infection were the NTD group.The positive rate of CAR was detected by flow cytometry,the cytotoxic-ity of the cells was detected by lactate dehydrogenase(LDH)release assay,the secretion level of the cytokine in-terferon γ(IFN-γ)was detected by enzyme-linked immunosorbent assay(ELISA),and the antitumor activity of CD30 CAR-T in mice was further detected by a mouse xenograft tumor model.Results A comparison was made between the multi-chain CAR-T targeting CD30 and the single-chain second-generation CAR-T.It was found that the antitumor effect of the multi-chain CAR-T was similar to that of the single-chain CAR-T.However,it was worth noting that the IFN-γ secretion level of the multi-chain CAR-T was higher(P<0.001).More importantly,in the mouse tumor model experiment,the multi-chain CAR-T achieved complete tumor regression.Conclusion The multi-chain CAR-T targeting CD30 is superior to the traditional single-chain CAR-T in terms of antitumor activity.